Form 4: Axsome Therapeutics Executive Acquires Stock Options and Restricted Stock Units

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, reports acquisition of stock options and restricted stock units.

Summary

• Mark L. Jacobson, the Chief Operating Officer of Axsome Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
• On February 27, 2024, Jacobson acquired 32,825 employee stock options with an exercise price of $0.00.
• These options vest in equal quarterly installments over four years, becoming fully vested on February 27, 2028.
• Jacobson also acquired 18,027 restricted stock units (RSUs) on the same date.
• 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three equal annual installments, fully vesting on February 27, 2028.
• Vested shares will be delivered upon a Change in Control, separation of service, or seven years from the grant date.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The vesting schedule suggests a long-term commitment, which is generally viewed positively.

Positives

• The grant of stock options and RSUs to the COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade in their company's stock. This filing indicates compensation in the form of stock options and restricted stock units.

Comparison to Industry Standards

• Stock options and RSUs are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and align executive interests with shareholder value.
• Vesting schedules are typically structured to encourage long-term commitment, often over a period of 3-4 years.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholder value by aligning executive interests with company performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates